News | May 14, 2025
Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Findings likely to generate hypotheses about potential new uses of drugs
Awards highlight Avantor's commitment to the Biopharma industry
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Subscribe To Our Newsletter & Stay Updated
